Evidence map›Paper›PMID 20373667›Full record

ReviewDialogues in clinical neuroscience2010

The past, present, and future of direct-to-consumer genetic tests.

Agnar Helgason, Kári Stefánsson

Open access · diamondAbstract readHistorical ArticleReview
In one paragraph

Review in Dialogues in clinical neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Variations in predicted risks in personal genome testing for common complex diseases.Genetics in medicine : official journal of the American College of Medical Genetics · 2014
    Article
  7. Article
  8. Article
  9. Article
  10. Navigating a research partnership between academia and industry to assess the impact of personalized genetic testing.Genetics in medicine : official journal of the American College of Medical Genetics · 2012
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Agnar HelgasondeCODE Genetics, Reykjavik, Iceland. agnar@decode.is
Kári Stefánsson
University of Iceland · IS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Technological advances in the field of human genetics have resulted in a wave of discoveries of common DNA sequence variants that are associated with a risk of common complex diseases, such as heart attack, that account for a substantial proportion of morbidity, mortality, and health care costs in most contemporary populations. The overall predictive power of these sequence variants can be considerable, due to the high incidence of these diseases and the sheer number of associations that have been discovered. Health care providers have been slow to utilize this knowledge for preventative medicine. However, several companies have taken on a translational role by offering genetic tests based on these discoveries direct to consumers. In this paper, we review the current state and future prospects of such genetic tests, as scientists involved both in the discovery of disease associations and the development of genetic tests.

Indexed as

Genetic Predisposition to DiseaseGenetics, MedicalGenetic TestingGene FrequencyGenetic VariationGenome, HumanGenotypeHistory, 20th CenturyHistory, 21st CenturyHumans

Identifiers

PMID20373667
PMCPMC3181949
OpenAlexW1480373472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.